Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07157774 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

Name: Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) — clinical trial record (NCT07157774)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MOVE-Lp(a)

StatusRecruiting

PhasePhase 3

SponsorEli Lilly and Company

Started2025-09-02

View on ClinicalTrials.gov ↗

The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.

Amendment history 6 changes detected by DataLookout

2026-08-22

Trial sites expanded: 785 → 801 locations

2026-08-08

Trial sites expanded: 772 → 785 locations

2026-07-21

Trial sites expanded: 769 → 772 locations

2026-07-08

Trial sites expanded: 762 → 769 locations

2026-06-24

Trial sites expanded: 752 → 762 locations

2026-05-13

Trial sites expanded: 751 → 754 locations

Trial Details

NCT Number	NCT07157774
Lead Sponsor	Eli Lilly and Company
Conditions	Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Enrollment	10,450 participants
Start Date	2025-09-02
Primary Completion	2031-03 (estimated)
Study Completion	2031-03 (estimated)
Updated on ClinicalTrials.gov	2026-09-04